Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
12,221 people get ARNA articles and Market Currents by email alert.
Get email alerts on ARNA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Arena's CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, Nov 6, 2012 • 10 Comments
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call TranscriptTue, Nov 10, 2009
-
Arena Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptFri, Mar 13, 2009
-
Arena Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptThu, Oct 30, 2008
-
Arena Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptTue, Aug 5, 2008
-
Arena Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptWed, May 7, 2008 • 1 Comment
-
Arena Pharmaceuticals Q4 2007 Earnings Call TranscriptMon, Mar 10, 2008
-
Arena Pharmaceuticals Q3 2007 Earnings Call TranscriptWed, Oct 17, 2007
-
PR Newswire (May 10, 2013)
-
at CNBC.com (May 2, 2013)
-
PR Newswire (May 2, 2013)
-
at CNBC.com (Apr 11, 2013)
-
PR Newswire (Apr 5, 2013)
-
at MarketWatch.com (Mar 4, 2013)
-
PR Newswire (Feb 27, 2013)
-
PR Newswire (Feb 6, 2013)
-
at CNBC.com (Feb 5, 2013)
-
PR Newswire (Jan 2, 2013)
-
at CNBC.com (Dec 17, 2012)
-
at MarketWatch.com (Dec 14, 2012)
-
PR Newswire (Dec 6, 2012)
-
PR Newswire (Nov 21, 2012)
ARNA vs. ETF Alternatives
Company Description
We are a clinical-stage biopharmaceutical company committed to discovering and developing innovative therapies offering significant medical advances and new options for patients. We are focused on discovering, developing and commercializing oral drugs in four major therapeutic areas:... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, June 27, 2012, 2:30 PM Orexigen (OREX +17%) is another benificiary of Arena's (ARNA) good fortune today. Contrave is an investigational medication OREX has been working on that also focuses on the treatment of obesity, however it's still in the developmental stages. Comment! [Healthcare, On the Move]
- Wednesday, June 27, 2012, 2:12 PM Arena Pharmaceuticals (ARNA +32%) will be hosting an online conference call to discuss the FDA's approval of Belviq at 2 PM EST. (Webcast Link) 1 Comment [Healthcare]
- Wednesday, June 27, 2012, 2:02 PM Vivus (VVUS +9%) spikes to a year high on the back of the the FDA's approval of Arena Pharmaceuticals' (ARNA +38%) weight-loss drug Belviq. Regulators are set to make a decision on its Qnexa diet drug on July 17. 5 Comments [Healthcare, On the Move]
- Wednesday, June 27, 2012, 1:47 PM Arena Pharmaceuticals (ARNA +38%) resumes trading at $13.50 following the FDA's approval of its weight-loss drug Belviq - formerly known as lorcaserin. 9 Comments [Healthcare, On the Move, Breaking News]
- Wednesday, June 27, 2012, 1:29 PM Arena Pharmaceuticals (ARNA -1.4%) is set to resume trading at 1:45 EST, with quotes resuming at 1:40 EST. Comment! [Breaking News, Healthcare]
- Wednesday, June 27, 2012, 1:16 PM Shares of Arena Pharmaceuticals (ARNA -1.4%) are halted pending news that U.S. regulators have approved its weight-loss drug Belviq - formerly known as lorcaserin. The announcement is expected but notable nonetheless, due to the fact that it will be the first new prescription diet pill to be cleared for sale in the U.S. in over 13 years. 12 Comments [Healthcare, On the Move]
- Monday, June 25, 2012, 4:04 PM Shares of Arena Pharmaceuticals (ARNA -7.2%) continue Friday's downward trajectory after minutes from the May 10th FDA panel on the company's obesity drug lorcaserin were posted, and don't show the in a favorable light. Many panelists appear to have voted yes, but only reluctantly. 20 Comments [Healthcare]
-
Monday, June 25, 2012, 9:06 AM
Premarket gainers: LXRX +8%. TEVA +7%. QSFT +6%.
Losers: VTUS -53%. MNTA -23%. SHPGY -12%. CEL -7%. ALU -6%. ARNA -6%. NOK -5%. ING -5%. Comment! [On the Move] - Friday, June 22, 2012, 12:25 PM The selling pressure seen by Arena Pharmaceuticals (ARNA -16.4%) remains intense, as shares give back a healthy chunk of their recent gains. Possibly hurting Arena's cause is an article from SA's Shane Blackmon, who notes Arena's rally has been fueled by short-covering (22% of the float was shorted as of May 31), and argues "a bear raid seems inevitable" ahead of the FDA's expected June 27 decision on the company's Locaserin weight-loss drug. 28 Comments [Healthcare, On the Move, Quick Ideas]
- Friday, June 22, 2012, 9:42 AM Frenzied activity continues for Arena Pharmaceuticals (ARNA), now down 8% after dropping more than 18% in a matter of minutes, a follow-on to its 11% gain on heavy volume yesterday. As the run-up to an FDA decision on its lorcaserin diet drug continues, the company had risen 39% this week before today's open. 21 Comments [Healthcare, On the Move]
- Monday, June 18, 2012, 1:05 PM Arena (ARNA +12.5%) shares continue their upward trajectory ahead of the FDA's decision, which is still nine days away, on whether to approve the company's lorcaserin diet drug. Investors clearly believe the agency will approve the treatment, although market players aren't totally sure why shares are flying so high. 36 Comments [Healthcare, On the Move]
- Wednesday, June 13, 2012, 11:53 AM Arena's (ARNA) shares have been flying recently and are up another 3.1% today. While the FDA is expected to soon approve Arena's weight loss drug lorcaserin, market players aren't totally sure why shares are rocketing. One reason could be short covering, and another optimism that the FDA approval will come without the need for a risk-management plan. 11 Comments [Healthcare, On the Move]
- Tuesday, June 12, 2012, 3:37 PM Arena Pharmaceuticals (ARNA +9.8%) and Vivus (VVUS +2.9%) both move higher today after Five Star Equities issued a press release highlighting their weight loss drugs, saying they may be the first in a lucrative market. 2 Comments [Healthcare, On the Move]
- Tuesday, May 22, 2012, 10:09 AM Arena Pharmaceuticals (ARNA) +4.7% to $6.24 after it yesterday completed its secondary public offering and underwriters fully exercised their option to purchase additional stock. Arena sold almost 12.65M shares at $5.50 each, raising nearly $70M. Comment! [Healthcare, On the Move]
-
Wednesday, May 16, 2012, 9:05 AM
Premarket gainers: OSUR +30%. COGO +15%. SINA +12%. ABMD +9%. VELT +8%. FTR +6%.
Losers: CLNT -29%. JCP -15%. TAXI -9%. NBG -8%. ANF -7%. ARNA -6%. WHX -5%. KERX -5%. Comment! [On the Move] - Tuesday, May 15, 2012, 4:07 PM Arena Pharmaceuticals (ARNA) slips in the post session after the company says it's filed a secondary offering with no share amount yet given. Jefferies and Piper Jaffray will act as joint book-running managers. Shares -2.7% AH. 2 Comments [Healthcare]
-
- View all 0 replies
-
- View all 1 replies
-
Day Trader001: $8.00 has been a good bounce mark, but VVUS reports Monday that could affect the sector.
-
Retail Investor
$DNDN $AMRN $TEVA $ARNA $CLSN $SPY $TARO Posts Strong Results -> http://bit.ly/THNRyQ - View all 0 replies
-
- View all 0 replies
-
- View all 5 replies
-
Crazysight: Well u can't pick them all. Tthought it would probably keep falling the rest of the week, but the areniacs seem 2 b back with a vengeance. -
Crazysight: What a stock this ARNA is though. Never a dull moment with it!
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
StockwatchmanCHI
Streamed the $ARNA presentation at $JPM - things seem to be looking pretty good with a lot of potential positives in the first half of 2013 - View all 0 replies
-
Brian L. Wilson
Speculation on rise for $ARNA and $VVUS as the drugs are set to compete. Arena's presentation at $JPM soon http://seekingalpha.com/a/nn23 - View all 0 replies
LATEST REPLIES
-
- View all 3 replies
-
-
-
- View all 3 replies
-
KAYOS978: just testing a key support level. Notice that it bounce off the 7 dollar mark. Keep an eye on this level, could run, or sell off massively.
-
TOAN VINH TRAN: good,revenue up 500% with higher losse (missed estimation $0.040.
-
- View all 2 replies
-
JayWright: U can pick some up for around 6.20ish by selling Sep $7 calls with premium at $.79. -
-
investinguru
I feel like the only real hope for a huge gain (reason many of us are here) is if ARNA gets bought out - View all 2 replies
-
-
investinguru: facebook just wants to do everything. Social networking, mobile phones, and now this lol
-
- View all 10 replies
-
morpin: thanks zpyles... makes sense. I could have sworn I saw ask prices being entered that where lower than the bid prices today.
-
-
Day Trader001
People's expectations of ARNA / VVUS exceeded the hype! The drug is not even on the market yet, it just takes time to make money. - View all 18 replies
-
-
-
- View all 9 replies
-
realornot: You will have so much pain to endure if continue the hold. Hopefully, you have less than 100 shares on them.
-
phemale60: over 500 at $10 --held since 2011 (lost $ aft. 2010 adcomm) -- my experience is I sell and it goes up -- never fails! Was up 197% now 116%
-
- View all 4 replies
-
-
investinguru: looking at this realisticly we could see a small gain tomorrow of about 3 or 4 % from our 10% loss today :(
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Day Trader001
July 30, 2012 /PRNewswire/ -- Eisai Inc. and ARNA Pharmaceuticals, Inc. announced today that Arena has.. - View all 4 replies
-
Day Trader001: Arena will continue in its oversight role for the global development of BELVIQ while working closely with Eisai for the....
-
-
- View all 13 replies
-
-
-
Day Trader001
"The large pharm companies are on the edge of their seats looking at Arena" Stephen Brozak president WBB Securities in Clark, NJ ARNA VVUS - View all 27 replies
-
phemale60: You're right. Still hurts tho. Have 500 shares but 430 average $9.73. Rest got in separate acct. bef. FDA too high, so sold some at loss
-
phemale60: Kind of complicated. In IRA so not options - just simple trading. LOL -- except it ain't simple! pulling back near $23 again. Whew!! Time
-
Day Trader001
So was all that debate over who's better, ARNA or VVUS worth it? If you traded both you probably don't care right now! - View all 10 replies
-
kevin1533: dont be blinded by greed. safer is better. fyi i only sold few aug puts. so not really braggina bout this one. -
-
- View all 3 replies
-
-
kevin1533: yeah but dont want to cut it close even though im confident itll stay above 10